Infant food containing hydrolysed proteins

FIELD: food industry.

SUBSTANCE: invention relates to infant alimentation. One proposed application of fat, digestible carbohydrates and protein to produce a composition for therapy and/or prevention of adiposity as well as coexistent diseases. The protein includes at least 25 wt % of peptides with chain length from 25 to 30 amino acids (of total dry protein weight), the composition contains at least 12 mg of indigestible fermentable carbohydrates per 1 g of dry nutritious mixture weight. The composition is applied for baby feeding.

EFFECT: invention allows to prevent overgrowth and proliferation of adipcytes in the period of infancy (and, consequently, children's adiposity and secondary disturbances connected to it) due to combination of hydrolysed proteins and indigestible fermentable carbohydrates.

14 cl, 2 dwg, 1 tbl, 2 ex

 

The technical field to which the invention relates

The invention relates to baby food, namely the complete nutrient mixture and the use of such baby food for the prevention and/or treatment of childhood obesity.

The prior art prior to the invention of

Childhood obesity is an increasing problem in developed countries. For example, in the United States in 2000, about 15% of children (up to 11 years) were overweight, while in 1980 they were 7%. In Europe there is a growing number of children suffering from overweight.

It is very likely that overweight children will keep it as adults. Childhood obesity linked to high blood pressure, elevated lipids, and increased risk of diseases in later life, such as asthma, type 2 diabetes and cardiovascular disease. In addition, the presence of excess weight is considered Western civilization as the lack of attractiveness. Causes of childhood obesity include lack of regular exercise, sedentary lifestyle, dietary habits, socio-economic factors and genetic factors. Also the food at an early age plays an important role in the prevention of childhood obesity; Armstrong & 'reilly (2002, Lancet 359:2003-4) found that breastfeeding reduces the risk the development of childhood obesity.

Breastfeeding is the preferred method of feeding infants. However, there are circumstances that make breastfeeding impossible or undesirable. In such cases, a good alternative is infant formula and improved infant formula. Composition modernized infant formula or improved infant formula adapted in such a way that meets certain requirements for food growing and emerging infant. The diet of infant feeding (almost) completely depends on the composition of infant formula and water. In addition, it is impractical using conventional methods of eliminating obesity, such as limiting the number of absorbed calories, inhibiting the absorption of nutrients, increase satiety, reduce appetite or increase thermogenesis as at risk of not allowing deviations nutritional needs.

In WO 2004069265 describes the use of peptides derived from hydrolyzed whey protein, as an active ingredient for improving cholecystokin in the blood and for the prevention or treatment of overweight and/or obesity in animals, including humans, if necessary.

In WO 03074129 describes to notice food additives, has a therapeutic effect, containing the minerals of milk, including calcium, protein source, including casein fragment 106-169, and enzyme inhibitory peptides for the treatment of overweight. The composition of the supplements take in amounts effective to limit the increase of body weight and/or gain loss of body weight, as well as for maintaining good health, for the treatment of overweight, including obesity.

In WO 03005836 describes diet food products for infants, children and adults with adequate levels and the ratio of medium chain fatty acids and omega-polyunsaturated fatty acids. The consumption of these diet products can contribute to the prevention of obesity in developing individuals and may contribute to the reduction of body weight in individuals trying to lose weight and reduce fat mass (for example, obese individuals).

Brief description of the invention

Infant feeding infant formula leads to increased afternoon insulin response compared with breastfed infants, the level of glucose in the blood is not reduced. Because it is believed that breastfeeding prevents childhood obesity, niela the elevated nutrient levels and insulin, and glucose, resulting from the feeding of infant formula compared to breast milk. Elevated levels of both insulin and glucose indicate the formation of insulin resistance in children receiving nursery infant formula, which presumably contributes to the development of childhood obesity.

The authors of the present invention unexpectedly discovered that the use of the composition in which the protein comprises hydrolyzed casein and hydrolyzed whey protein, results in a reduction in afternoon levels of both insulin and glucose compared with the composition containing solid casein and whole whey protein. Afternoon insulin response and after-meal glucose levels in the blood, observed after ingestion of hydrolyzed casein and hydrolyzed whey protein, were comparable and similar to that observed when breastfeeding.

Thus, the authors of the present invention have found that the combination of hydrolyzed casein and hydrolyzed whey protein can be advantageously used in the method of treatment and/or prevention of childhood obesity. The present invention is also suitable for use in the method of treatment and/or prevention of secondary disorders in children, Strada is observed from childhood obesity in particular one or more disorders selected from the group consisting of diabetes (type 2), insulin resistance, cardiovascular disease, hypertension, asthma, apnea during sleep, disorders of musculoskeletal system (in particular, the Shin bone and thigh bone) and arthritis.

In another aspect, the present invention relates to a method of treatment and/or prevention of childhood obesity, including obtaining the infant a composition comprising hydrolyzed casein, hydrolyzed whey protein and newsweaver.ie formatiruem carbohydrates.

A detailed description of the invention

In one aspect the present invention relates to the use of fat, digestible carbohydrates and protein, where the protein comprises at least 25 wt.% peptides with a chain length from 2 to 30 amino acids from the dry weight of the protein, to obtain the nutrient compositions for use in the method of treatment and/or prevention of childhood obesity.

In another aspect, the present invention relates to a method of treatment and/or prevention of childhood obesity, including the production of infant nutritional composition, including fat, digestible carbohydrates and proteins, where the protein comprises at least 25 wt.% peptides with a chain length from 2 to 30 amino acids from the dry weight of the protein.

In another aspect of the above examples, the giving and method may be suitable for use in the method of treatment and/or prevention of type 2 diabetes, insulin resistance, cardiovascular disease, hypertension, asthma, apnea during sleep, disorders of musculoskeletal system (in particular, the Shin bone and thigh bone) and arthritis in patients suffering from childhood obesity.

In another aspect, the present invention relates to a nutritional composition comprising from 35 to 60 EN.% fat, from 25 to 75 EN.% digestible carbohydrates, from 5 to 16 EN.% protein and newsweaver.ie formatiruem carbohydrates selected from the group consisting of polymaltose and galactooligosaccharides where the protein comprises at least 25 wt.% peptides with a chain length from 2 to 30 amino acids from the dry weight of protein; at least 50 wt.% proteins obtained from milk of mammals of the total dry weight of protein; casein and whey protein in a ratio of casein:whey protein from 10:90 to 90:10; and less than 15 wt.% free amino acids from the total mass of the protein.

Used herein, the term "childhood obesity" refers to a disease in which the child is obese or overweight. Childhood obesity may suffer as infants, and children. In particular, children with gender-specific BMI for age above the 85th percentile or above 95th percentile suffer from childhood obesity. BMI (body mass index) is an anthropometric measure, defined as the mass in kilog is the MMA, divided by squared height in meters. Table gender specific BMI for each age public, for example, at the National center for health statistics of the United States. If the child has gender-specific BMI for age above the 85th percentile or above 95th percentile, it means that 85% or even 95% of the population composed of children of the same age and sex, has a lower BMI.

Protein

The composition according to the invention contains protein, comprising at least 25 wt.% peptides with a chain length from 2 to 30 amino acids from the dry weight of protein. The number of peptides with a chain length from 2 to 30 amino acids, for example, can be determined as described by de Freitas et al., 1993, J. Agric. Food Chem 41:1432-1438.

The composition according to the invention preferably contains at least 50 wt.% protein is not breast milk from total protein, more preferably at least 90 wt.%. Preferably the composition according to the invention contains at least 50 wt.% protein of cow's milk from total protein, more preferably at least 90 wt.%. Preferably the composition according to the invention contains protein derived from acid whey and/or sweet whey with a reduced concentration of glycomacropeptides. As a rule, glycomacropeptide (GMP) with molecular weight of 8000 daltons represent a fragment of casein obtained from sivaram and, contains amino acid residues 106-109 Kappa-casein, and derived from Kappa-casein proteolytic effect of rennin (chymosin). GMP glycosylated. Glycosylated portion attached to the peptide skeleton GMP molecules, preferably includes from 7 to 8% of N-acetylneuraminic acid, known as sialic acid. In one embodiment of the present invention, the composition according to the invention includes whey protein derived from cow's milk, with high concentration of glycomacropeptides. Preferably the composition according to the invention includes a protein derived from β-casein and/or α-milk albumin. Preferably, the composition according to the invention contains hydrolyzed whey protein and hydrolyzed casein. Casein and whey proteins preferably are present in a weight ratio of casein:whey proteins from 10:90 to 90:10, more preferably from 20:80 to 80:20. This optimal range, because the amino acid composition of bovine casein closer amino acid composition of protein breast milk and whey protein is easily digested and is a larger ratio in breast milk.

The composition according to the invention preferably includes as hydrolyzed casein and hydrolyzed whey protein because the amino acid composition of bovine casein b is more similar amino acid composition of protein breast milk and whey protein is easily digested and is a larger ratio in breast milk.

The composition according to the invention preferably includes rice protein. Rice protein and its partial hydrolysate is Hypo-allergenic, easily digestible and have a balanced amino acid composition. To improve the amino acid balance of rice protein is preferably combined with essential amino acids such as lysine. In a preferred embodiment of the present invention rice protein is combined with vegetable protein, preferably a protein of peas or beans.

The composition according to the invention preferably contains from 5 to 16 EN.% protein, more preferably from 8.0 to 12.0 EN.% the protein. EN.% - reduction of the percentage of energy and represents the relative amount of each component contributing to the total caloric value of the drug. Energy in the composition is obtained from the digestion of carbohydrates, protein and fat. Used herein, the term protein refers to the amount of proteins, peptides and free amino acids.

The composition preferably contains from 1.0 to 6.0 g, more preferably from 1.0 to 2.5 g of protein per 100 ml of ready-to-use composition. The composition preferably contains at least 7.0 wt.%, more preferably 8.0 wt.% protein by weight of the total dry composition. Preferably the composition comprises not more than 40 wt.%, more preferably a maximum of 20 wt.% protein by weight of the total dry composition. Wt.% protein of total dry mass of the composition is calculated according to the percentage ratio Kjeldal, N·6,25, in which N represents the number of measured nitrogen.

The composition preferably contains at least 50 wt.%, preferably 80 wt.%, most preferably about 100 wt.% the protein hydrolysate of the total weight of a protein.

The composition preferably contains less than 10 g of free amino acids per 100 g of protein, more preferably less than 7, the Relatively low content of amino acids results in a low osmolality and, thus, prevents disorder of the gastrointestinal tract/digestive system such as diarrhea. Low content of amino acids has additional value to reduce the bitter taste; free amino acids give a formula bitter taste. In addition, free amino acids are absorbed worse in the gastrointestinal tract compared with peptides. In addition, the number of free amino acids in the composition of the invention preferably is limited.

The composition according to the invention contains at least 25 wt.% peptides with a chain length from 2 to 30 amino acids from the total % protein, preferably at least 40 wt.%, most preferably, at least 50 wt.%. Preferably the composition according to the invention contains, at the very measures which, 15 wt.% peptides with a chain length from 2 to 15 amino acids from protein, preferably at least 40 wt.%, most preferably at least 50 wt.%. Peptides with a chain length of 15 to 30 amino acids are preferably at least 0.5 wt.%, more preferably at least 1 wt.%, most preferably at least 5 wt.% the protein. Preferably the composition according to the invention contains peptides with a chain length of more than 30 amino acids from 0.5 to 8 wt.% of the total protein, more preferably from 0.7 to 7 wt.%, and most preferably from 0.75 to 5 wt.%. The presence of short peptides (with chain length from 2 to 15 amino acids) improves digestion of proteins, and consequently, they are included in the composition. The presence of peptides with a chain length of 15 to 30 amino acids allows the digestive system of an infant to get used to the thumb and/or one-piece peptides. Preferably at least 80 wt.%, more preferably at least 95 wt.% protein component have a chain length of more than 4, more preferably more than 9 amino acids. In other words, preferably less than 20 wt.%, more preferably, less than 5 wt.% protein component contains free amino acids and peptides with a chain length up to and including 4, more preferably up to and including the 9 amino acids due to the low osmolality, Luchenok taste and improved digestibility of the product.

The composition according to the invention preferably contains a protein with a degree of hydrolysis of protein from 5 to 25%, more preferably from 7.5 to 21%, most preferably from 10 to 20%. The degree of hydrolysis is defined as the percentage relationships of peptides that were torn enzymatic hydrolysis, with a 100% potentially present all peptide bonds. Proteins with the above degree of hydrolysis provide enough peptides with a chain length from 2 to 30.

Digested carbohydrates

The composition according to the invention preferably contains digestible carbohydrates, preferably lactose. The composition preferably contains from 25 to 75 EN.% digestible carbohydrates, more preferably from 40 to 55 EN.%. The composition according to the invention preferably contains from 6 to 19 g digestible carbohydrates per 100 ml, more preferably from 6 to 10 g per 100 ml of ready to use liquid composition. 100 g dry weight of the composition, respectively, contain from 40 to 75 grams of digestible carbohydrates.

Because it is very important that insulin response and glycemically index were low, preferably at least 35 wt.%, more preferably at least 50 wt.%, even more preferably at least 75 wt.%, most preferably at least 95 wt.% digestible carbohydrates in the present compositions are lactose intolerant.

Fat

The composition according to the invention contains fats. The amount of saturated fatty acids is preferably less than 58 wt.% by weight of the total fatty amino acids, more preferably less than 45 wt.%. The concentration of monounsaturated fatty acids is preferably in the range from 17 to 60% by weight of the total fatty acids. The concentration of polyunsaturated fatty acids in the present compositions is preferably from 11 to 36% by weight of the total fatty acids. Fats are essential for the growth of the infant, while, on the other hand, the fat may contribute to the emergence of childhood obesity. Fat mixture according to the invention in the composition of the invention containing protein, is considered to be optimal to prevent childhood obesity.

Must be present in sufficient quantities and be in a balanced ratio of essential fatty acids: linolenic acid (LA; omega 6 fatty acid) and α-linolenic acid (ALA; omega 3 fatty acid), because the deficit and imbalance LA and ALA are associated with disorders such as insulin resistance and obesity. In addition, preferably the composition contains from 0.3 to 1.5 g LA per 100 ml ready-to-use liquid composition and at least 50 mg ALA per 100 ml of the Composition according to the invention preferably contains from 1.8 to 12.0 wt.% LA in terms of dry weight to what notizie and at least to 0.30 wt.% ALA, calculated on the dry weight of the composition. The mass ratio of LA/ALA is preferably from 5 to 15. Preferably the composition according to the invention contains long-chain polyunsaturated fatty acids (LC-UFA), more preferably eykozapentaenovuyu acid (EPA) and/or docosahexaenoic acid (DHA). As DHA and EPA, which improves insulin sensitivity, in addition, mainly included in the composition according to the invention. Fat composition with properties as described above, is considered to be acting synergistically with hydrolyzed protein for the prevention and/or treatment of childhood obesity.

The composition preferably contains from 2.1 to 6.5 g fat per 100 ml of ready to use liquid form. In terms of the dry weight of the composition preferably contains from 12.5 to 30 wt.% fat. The composition according to the invention preferably contains from 35 to 60 EN.% fat, more preferably from 39 to 50 EN.% fat.

Newsweaver.ie formatiruem carbohydrates

Newsweaver.ie formatiruem carbohydrates are carbohydrates that are in the colon of human solid after oral ingestion. Used herein, the term "formatiruem" refers to the ability to undergo (anaerobic) destruction and move on with the help of microorganisms in the lower part of the gastrointestinal tract (e.g., the colon) in the form of smaller molecules, and they are the NGOs short-chain fatty acids and lactate. Terminterest can be determined by the method described in Am. J. Clin. Nutr. 53, 1418-1424 (1991).

Newsweaver.ie formatiruem carbohydrates (NDFC) have a regulatory effect on glucose levels in the blood, because they normalize the emptying of the gastrointestinal tract and reduce the period of passage through the small intestine.

This impact is short-chain fatty acids derived from oligosaccharides in the colon, due to the so-called ileal-colonic inhibition refers to inhibition of gastric emptying due to nutrients under the age of ileo-colonic anastomosis. Short-chain fatty acids can also reduce the time of emptying of the ileum. In addition, it is considered that the NDFC and hydrolyzed proteins have a synergistic effect in the prevention and/or treatment of childhood obesity.

According to a preferred variant implementation of the present invention the composition comprises one or more neoslavery formatiruem carbohydrates. Preferably the composition contains from 0.1 to 1.5 g, preferably from 0.2 to 1.0 g NDFC per 100 ml ready-to-use liquid composition. Preferably the composition contains at least 0.5 wt.% NDFC of the total dry weight of the composition, more preferably at least 1.2 wt.%, Naib is more preferably at least 2.5 wt.%. Preferably the composition includes a maximum of 15, more preferably up to 12, most preferably a maximum of 8 wt.% NDFC by weight of the total dry composition. Preferably the composition contains at least one NDFC selected from the group consisting of polymaltose, fructo-oligosaccharides, galactooligosaccharides, partially gidrolizovannogo galactomannan, the galacturonic acid comprising oligosaccharides and oligosaccharide polydextran resistant to digestion in the gastrointestinal tract of man. Preferably the composition according to the invention contains a mixture of galactooligosaccharides. In a separate preferred embodiment of the present invention the composition comprises polymaltose. Polymaltose reduces total cholesterol, LDL (LDL) cholesterol, VLDL level (LDL), very low density and triglyceride levels in patients suffering from obesity. In another preferred embodiment of the present invention the composition comprises a mixture of transplantationfollow and polymaltose. The synergistic mixture produces the highest number of short-chain fatty acids. In a preferred embodiment of the present invention, the mass ratio of transplantationfollow/polymaltose is from 99/1 to 1/99, more preferably from 98/2 on the 1/9, even more preferably from 98/2 to 1/1.

Polymaltose is a polysaccharide carbohydrate comprising chain with β-linked fructose units with degree of polymerization or average degree of polymerization of 10 or more. The degree of polymerization or average degree of polymerization of polymaltose is preferably below 100. Polymaltose includes inulin, Levan and/or mixed - polifruktan. The most preferred polymaltose is inulin. Polymaltose suitable for use in the compositions, is also commercially available, for example, from Raftiline®HP (Orafti).

Transplantological (TOS) are galactooligosaccharide where the majority of galactose units (preferably at least 90% of the galactose units of the total mass of monosaccharide units, more preferably at least 95%) linked β-linkages. Most preferably the use of these TOS, in which the majority of galactose units (at least 50%, preferably at least 90%) linked β - (1,6) glycosidic bonds. These TOS, as, for example, Vivinal®GOS (Borculo Domo Ingredients, Zwolle, Netherlands).

Probiotics

In a preferred embodiment of the present invention the composition further comprises a probiotic. Probiotics are live microorganisms that reach t is lstay intestine alive in oral and exert beneficial effects. Preferred probiotics belong to the genus Bifidobacteria and/or Lactobacilli. Proteolytic enzymes probiotics optionally hydrolyzing the protein source in the gastrointestinal tract, providing, thus, a synergistic effect. In addition, probiotics improve intestinal flora, improving, thus, the formation of short-chain fatty acids, which have a normalizing effect on the level of glucose in the blood. In addition, particularly preferably, the composition according to the present invention included probiotics and NDFC, which serve as substrate for probiotics. Preferably, the probiotic is present in the composition in a concentration of from 103up to 1011more preferably from 105up to 1010most preferably from 108up to 109kolonialismus units per g dry weight of the composition. Most preferably, the composition according to the invention includes Bifidobacteria breve and/or Lactobacillus paracasei. The authors of the present invention have found that the growth of these bacteria is weakened in infants, children receiving infant formula, compared with breastfed.

Polyamine

The present invention also relates to the use of polyamines for the treatment and/or prevention of childhood obesity and/or treatment and/or prevention of type 2 diabetes, asthma, arthritis, is hypertensie, syndrome, sleep apnea, cardiovascular diseases and/or disorders of the musculoskeletal system in patients suffering from childhood obesity. In a preferred embodiment of the present invention, the composition according to the invention includes a polyamine. In another embodiment of the present invention, the composition includes polyamine and present protein hydrolysate. Preferably polyamine selected from the group consisting of cadaverine, putrescine, spermine and spermidine. Most preferably the composition contains spermidine and/or spermine. The composition according to the invention preferably will contain from 0.5 to 200 μg of polyamine per 100 ml ready-to-eat product, more preferably from 2 to 40 μg. Preferably the composition includes at least two or more compounds selected from the group consisting of cadaverine, spermine, spermidine and putrescine. Preferably the composition includes from about 10 to 90 wt.% spermine, from 10 to 90 wt.% spermidine, from 0 to 90 wt.% of putrescine and from 0 to 20 wt.% cadaverina of the total mass of polyamines. Preferably the composition according to the invention contains as a source of polyamines lactic acid bacteria, yeast extract and/or the extract of the pancreas. Polyamine play an important role in the prevention and/or treatment of childhood obesity, because they modify the afternoon kinetics and influence the digestibility of proteins.

Liquid composition

The composition of the present invention is preferably introduced in liquid form. In order to meet the requirements of the caloric composition preferably contains from 50 to 200 kcal/100 ml, more preferably from 60 to 90 kcal/100 ml Nutrient composition preferably includes from 5 to 16 EN.% protein, 35 to 60 EN.% fat and 25 to 75 EN.% carbohydrate. As a rule, osmollnosti this song is from 150 to 420 mosmol/l, preferably from 260 to 320 mosmol/L. Low osmollnosti helps to reduce the stress of the gastrointestinal tract, for example, reduces the incidence of diarrhea, especially in infants.

Preferably the composition is a liquid with a viscosity of below 35 SP. A suitable composition is in powder form, which can be recovered water to a liquid form or in the form of a liquid concentrate that should be diluted with water.

Daily dosage

If the composition is in liquid form, the preferred daily volume is from about 80 to 2500 ml, more preferably from about 450 to 1000 ml per day, which is a suitable number for the baby.

Treatment

The composition according to the present invention can mainly be used in the method of treatment and/or prevention for children is about obesity. Also the composition of the present invention can be used mainly for the treatment and/or prevention of type 2 diabetes, hypertension, cardiovascular disease, arthritis, asthma, apnea during sleep and/or disorders of the musculoskeletal system (in particular, the Shin bone and thigh bone) in infants suffering from childhood obesity.

The composition of the present invention infants are preferably administered orally. In particular, the composition used in the method of infant feeding and/or stimulating the growth of the infant. In particular, the composition suitable for the prevention of childhood obesity and/or secondary disorders caused by them. On this basis the composition is administered predominantly breast-fed infants from 0 to 24 months, preferably infants from 0 to 18 months.

Description of the drawings

Figure 1. Afternoon the glucose level in blood of rats treated with the composition comprising lactose, whole whey protein and whole casein (●), the composition comprising lactose and hydrolyzed whey protein and hydrolyzed casein (○) or breast milk (▲).

Figure 2. Afternoon insulin levels in the blood of rats treated with the composition comprising lactose, whole whey protein and whole casein (●), the composition comprising lactose and hydrolyzed Siva otechny protein and hydrolyzed casein (○) or breast milk (▲).

Examples

Example 1

Protein preparations

Whole whey protein Deminal 90 was taken from Borculo Domo Ingredients. Whole casein protein was obtained from skimmed milk powder in which the ratio of casein/whey protein is 4. Whey protein and casein protein mixed in such a way as to obtain a ratio of 40 wt.% casein protein and 60 wt.% whey protein.

Hydrolyzed whey protein was obtained by hydrolysis of the drug acid serum as described in Example 1-4 WO 0141581. The degree of hydrolysis was 15%. Hydrolyzed casein took LacProdan DI-2038 (Arla Foods). Two drugs were mixed in a ratio of 40 wt.% hydrolyzed casein and 60 wt.% hydrolyzed whey protein.

Animals

20 adult male Wistar rats (aged 10 weeks at the beginning of the experiment) were housed individually. Animals were allowed water and food ad libitum (standard Rat Chow, Harlan). Animals received a permanent cannula in the jugular vein during surgery under anesthesia with isoflurane/N2O/O2to obtain blood samples without stress. All experiments on animals were allowed by the Committee to conduct experiments involving animals (DEC-Consult).

Treatment

4 hours after feeding 10 animals received 2 ml of the composition. Were tested three different compositions on the cross is the local models (experiments were separated by one week).

1. Breast milk (containing 11 mg of protein, 70 mg lactose 45 mg of fat per ml).

2. 17 mg of whey protein/casein and 86 mg of lactose in ml.

3. 17 mg of hydrolyzed whey protein and hydrolyzed casein and 86 mg of lactose on ml and subsequent collection of blood samples (200 μl) treated with heparin chilled tubes through t=0, 5, 10, 15, 30, 60, 90 and 120 minutes after feeding. Followed by the separation of plasma after centrifugation (10 min, 5000 rpm). Kept at -20°C prior to analysis.

Measurement of insulin levels

The plasma insulin was measured by radioimmunoassay (RIA, Linco) using the set and Protocol with the following amendments: all the analyzed volume is reduced four times.

Measurement of glucose level

Glucose in plasma was measured using oxidase-peroxidase method in 96-well tablet (Roche Diagnostics, #1448668).

The area of the curve, peak time, maximum peak height

The area curve (AUC) was determined using the linear formula of a trapezoid. Was calculated as the area of the curve for glucose and insulin to the animal during the early peak (t=0-30 minutes) and measured the full curve (t=0-120 minutes). Negative evaluation (when the response reached levels below main) subtracted. For animal determined the time and the level of glucose and insulin peak (the maximum concentration is lazmi all measured points).

Results

Afternoon peak glucose as well as insulin was lower in rats fed the whole whey protein and whole casein compared with rats treated with hydrolyzed whey protein and hydrolyzed casein. It can be seen in figures 1 and 2 and table. Time to peak glucose is lower in rats treated with hydrolyzed whey protein and hydrolyzed casein, compared with rats receiving whole whey protein and whole casein. The area curve (AUC) of glucose is lower in rats treated with hydrolyzed whey protein and hydrolyzed casein, compared with rats receiving whole whey protein and whole casein. According to the results of the reception hydrolyzed proteins afternoon levels of glucose and insulin kinetics were similar in the greater degree they also observed when receiving breast milk (see drawings).

On insulin resistance indicate peak glucose, peak insulin and AUC of glucose and insulin during periods of time (0-30). Low scores were noted in rats fed breast milk, and rats treated with hydrolyzed casein and hydrolyzed whey protein. High marks were noted in rats fed the non-hydrolyzed whey protein and casein.

The impact of whole gidrolizovannykh proteins on afternoon peak time, the maximum peak height and the area of the curve of glucose and insulin
impactIntegral proteinsHydrolyzed proteinsBreast milk
temporary peak (m±se)
glucose
insulin
7,5±3,8
8,3±0,8
11,5±2,6
8,3±1,4
12,0±2,4
11,7±1,2
peak (±se)
glucose (g/l)
insulin (mg/l)
0,46±0,10
1,51±0,44
0,31±0,07
1,11±0,20
0,33±0,08
1,41±0,27
AUC 30 (±se)
glucose (min g/l)
insulin (min g/l)
5,3±1,6
14,4±7,7
3,4±2,1
12,5±3,8
3,6±2,3
17,3±4,3
AUC 120 (±se)
glucose (min g/l)
insulin (min g/l)
8,1±4,9
-9,6±23,2
of-1.5±9,0
10,6±7,6
3,5±6,9
18,2±21,3
peak glucose* peak insulin5,9±1,83,9±0,64,5±0,6
AUC glucose* AUC insulin (0-30)128±7881±4184±53

Example 2

Powdered milk formula for infants with indication on the packaging that the product is suitable for the prevention of childhood obesity or diseases associated with childhood obesity, which can be recovered water (15.6 g of powder to 100 ml final volume)containing 100 ml of ready to use product:

Source of protein11,9 g 11 EN.%
Fat3,3 g 40 EN.%
Digested carbohydrates8.7 g 49 EN.%
Not digestible formatiruem carbohydrates20.8 g

1. Hydrolyzed whey protein, hydrolyzed casein, the ratio of 6/4 by weight, as described in Example 1.

2. 0,72 g transplantationfollow (present in Vivinal GOS, Borculo Domo, The Netherlands) and 0.08 inulin (Raftiline HP, Orafti, Belgium).

1. Do not use grease, USA is by carbohydrates and protein where the protein comprises at least 25 wt.% peptides with a chain length from 2 to 30 amino acids from the total dry weight of the protein, and where the composition includes at least 12 mg not digestible formatiruem carbohydrate per g dry weight of the nutritional composition, to obtain a nutritional composition for use for the treatment and/or prevention of childhood obesity.

2. The use according to claim 1, where the nutritional composition comprises at least 7 wt.% protein of total dry weight of the nutritional composition.

3. The use according to claim 1 or 2, where the composition includes hydrolyzed whey protein and hydrolyzed casein.

4. The use according to claim 1 or 2, where the nutritional composition is intended for oral administration.

5. The use according to claim 1 or 2, where the nutritional composition comprises from 5 to 16 EN.% protein, 35 to 60 EN.% fat and 25 to 75 EN.% carbohydrates.

6. The use according to claim 1 or 2 where the protein includes
d) at least 50 wt.% proteins obtained from milk of a mammal by weight of the total protein;
e) casein and whey protein in a weight ratio of casein : whey protein, comprising from 10:90 to 90:10; and
f) less than 15 wt.% free amino acids from the total mass of the protein.

7. The use of fat, digestible carbohydrates and protein, where the protein comprises at least 25 wt.% peptides with a chain length from 2 to 30 amino acids from the total dry weight of the protein and where kω is azizia includes at least 12 mg not digestible formatiruem carbohydrate per g dry weight of the nutritional composition, to obtain a nutritional composition for use for the treatment and/or prevention of type 2 diabetes, asthma, arthritis, hypertension, syndrome, sleep apnea, cardiovascular diseases and/or disorders of the musculoskeletal system in patients suffering from childhood obesity.

8. The use according to claim 7, where the nutritional composition comprises at least 7 wt.% protein of total dry weight of the nutritional composition.

9. The use according to claim 7 or 8, where the composition includes hydrolyzed whey protein and hydrolyzed casein.

10. The use according to claim 7 or 8, wherein the nutritional composition is for oral administration.

11. The use according to claim 7 or 8, wherein the nutritional composition comprises from 5 to 16 EN.% protein, 35 to 60 EN.% fat and 25 to 75 EN.% carbohydrates.

12. The use according to claim 7 or 8, wherein the protein includes
d) at least 50 wt.% proteins obtained from milk of a mammal by weight of the total protein;
e) casein and whey protein in a weight ratio of casein : whey protein, comprising from 10:90 to 90:10; and
f) less than 15 wt.% free amino acids from the total mass of the protein.

13. Nutritional composition comprising from 35 to 60 EN.% fat, from 25 to 75 EN.% digestible carbohydrates, from 5 to 16 EN.% protein and not digestible formatiruem carbohydrates selected from the group consisting of polymaltose and galactooligosaccharides, where the protein is involved in the t
a) at least 25 wt.% peptides with a chain length from 2 to 30 amino acids from the total dry weight of protein;
b) at least 50 wt.% proteins obtained from milk of a mammal by weight of the total protein;
c) casein and whey protein in a weight ratio of casein : whey protein, comprising from 10:90 to 90:10;
d) hydrolyzed whey protein and hydrolyzed casein and
e) less than 15 wt.% free amino acids from the total mass of the protein source.

14. The use of a composition according to item 13 to obtain a composition for feeding infants.



 

Same patents:

FIELD: food industry.

SUBSTANCE: this invention relates to application of at least one donor methyl group from the group of choline, methionine and betaine in a water-based drinking product immediately ready for consumption and to such a water-based drinking product immediately ready for consumption. In accordance with the invention concept, the drinking product contains a liquid food compound consisting of guanidinoacetic acid component and at least one donor methyl group from the group of choline, methionine and betaine.

EFFECT: addition of a methyl group donor selected from among choline, methionine and betaine, into the water-based drinking product immediately ready for consumption serves to increase the guanidinoacetic acid component stability.

11 cl, 2 ex

FIELD: medicine.

SUBSTANCE: invention is related to a food product for AIDS patients. Proposed is a food composition containing one or more acidic oligosaccharide(s) and one or more neutral oligosaccharide(s) and cysteine and/or a cysteine source. The acidic oligosaccharides are produced from pectin, pectate, alginate, chondroitin, hyaluronic acids, heparin, heparan, sialoglycanes, fucoidan, fucooligosaccharides or carageenan. The neutral oligosaccharides are selected from a group consisting of galactooligosaccharide, fructooligosaccharide, transgalactooligosaccharide, xylooligosaccharide, lactosucrose and arabinooligosaccharide where the said cysteine source is represented by N-acetylcysteine and/or diacetylcysteine, whey, beestings, egg whites or combination thereof.

EFFECT: invention enables preclusion and prevention of AIDS-related disfunctions.

12 cl, 1 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: invention is related to alimentation, in particular - to a method and composition for improvement of glucose and insulin balance. Proposed is a compound that includes: a protein source, a fat source and a carbohydrate source, the protein source to the fat source ratio being approximately 1:1:1, each source accounting for 15% - 45% of the total calorie content of the compound. The fat source accounts for approximately over 2% of the total calorie content of the composition in the form of linoleic acid (18:2). According to an alternative version, the food compound for normalisation of insulin and glucose in the organism contains a protein source, a fat source and a carbohydrate source at a ratio of 1:1:1, each of these components accounting for approximately a third of the total calorie content of the compound. Additionally proposed are a diet for enhancement of sensitivity to insulin, a method to reduce resistivity to insulin, a method to reduce insulin levels in the plasma during after dinner time, a method to delay occurrence of insulin in one's blood and a method to increase fat clearance during after dinner time envisaging usage of the above food compound.

EFFECT: invention allows to improve glucose regulation and insulin effect.

68 cl, 34 dwg, 38 tbl

FIELD: food industry.

SUBSTANCE: invention relates to a nutritive supplement, to a method of its production and application. The nutritive supplement, according to the invention, contains a protein source including milk protein isolate and/or canola protein, a fat source, a carbohydrate source and water and has calorific value 2.25 - 3.25 cal/ml and viscosity lower than 120 centiPoise. The method for production of the supplement envisages a mixture preparation of water and the protein source, the fat source, the carbohydrate source, the mixture treatment with direct injection of vapour, the mixture homogenisation. The nutritive supplement, according to the invention, is applied in combination with one or more medicaments during therapy of nutritional deficiency. The nutritive supplement has high calorific value and will be useful for persons suffering from body weight loss.

EFFECT: milk protein isolate treatment with application of direct injection of vapour allows to reduce viscosity of the nutritive supplement.

20 cl, 4 tbl, 12 ex

FIELD: food industry.

SUBSTANCE: invention is related to alimentary therapy. Proposed is a method providing for a cancer patient long-term alimentation and envisaging long-term administration of a nutritional product to the patient through a probe, the product containing a protein source providing for 14-25% of the product energy value and composed of whey (50% of energy value), glutamine (0.5% - 10% of energy value), leucine (0.8% - 3.5% of energy value), a carbohydrate source (20-55% of the product energy value) and a lipid source ( 25-40% of the product energy value). Optionally, the method envisages first administration of the above composition to a tumour cancer patient (through a probe) and then, upon normal metabolic status recovery - administration of a second composition for long-term alimentation that differs from the first composition in terms of formulation. Optionally, the method providing for a cancer patient long-term alimentation envisages administration of glutamine together with the above nutritional composition at least a week prior to commencement of the cancer therapy course.

EFFECT: invention enables to ensure well-balanced and efficient long-term through-probe alimentation of a cancer patient.

36 cl, 4 ex

Antioxidant complex // 2419362

FIELD: food industry.

SUBSTANCE: invention is related to food industry, in particular - to production of specialised products based on natural raw materials that may be used for alimentation of sportsmen as well as persons leading an active lifestyle. The antioxidant complex contains dihydroquercetin, L-carnozine, zinc citrate, selenopyran and vitamins A, C, E at a certain ratio. The invention enables reliable protection against multiple effects of oxidation and free radical impact.

EFFECT: maximally efficient dosage of the active components and absolutely accurately selected proportion of antioxidants in the formulated complex composition enable manifold intensification of the organism protective function and a significant cascade antioxidant action.

4 cl

FIELD: food industry.

SUBSTANCE: protein system contains a source of moisture, a combination of intact proteins, casein and partly hydrolysed milk protein and partly hydrolysed bean protein in a total quantity efficient for reduction of the required mixing time and/or shear force and for reduction of hardness development in the course of processing and storage of food products with extended storage life. Reduced staleness is ensured without bitterness imparted to the food product in case of usage of the protein mixture providing for a unique balance of partly hydrolysed and intact proteins and casein. Also considered are methods for manufacture of food products with protein mixtures.

EFFECT: invention enables production of protein systems for food products having enhanced storage life that preserve soft and moist texture in the course of time.

24 cl, 5 dwg, 5 tbl, 1 ex

FIELD: food industry.

SUBSTANCE: invention relates to a nutritional composition for babies. The composition includes a lipidic component and a digestible carbohydrate component. The lipidic component includes linolic acid (LA) and alpha-linolic acid (ALA), the LA/ALA weight ratio being from 2 to 7, the amount of LA being less than 14.5 wt %. of the total weight of fatty acids, the amount of ALA being from 1 wt % to 10 wt % of the total weight of fatty acids. The composition additionally includes at least one component chosen from the group consisting of: from 0.5 to 20 wt % of phospholipids of the total fat weight; from 0.035 to 1 wt % of choline of the total weight of the dry composition and from 0.001 to 0.1 wt % of uridine in the form of nucleotide, nucleoside and/or base of the total weight of the dry composition.

EFFECT: invention allows to prevent adiposity occurrence at an age of over 36 months by way of feeding the said nutritional composition to the baby at an age of under 36 months.

16 cl, 5 tbl, 4 ex

FIELD: food industry.

SUBSTANCE: invention refers to chemistry and food industry. Proposed is a mineral nutrient salt stabilised with amino acids and/or an ammonium salt. The salt is produced with organic acids anions or inorganic anions and metal cations bound to the amino acids and/or the ammonium salt. The metal cations are bound via ionic linkage to the anions and via covalent semi-polar linkage - to the amino acids amino group and/or the ammonium salt. The salt is represented by its general formula: {[Ac]n-·Men+ ← n [amino acid and/or ammonium salt]}·x H2O, where ← is covalent semi-polar linkage. Additionally proposed are a product and a food supplement containing such salt and a method for its production.

EFFECT: invention enables production of salts possessing improved taste and better solubility in water which renders them more biologically available.

16 cl, 2 dwg, 2 ex

FIELD: food industry.

SUBSTANCE: invention relates to food industry, namely, to production of biologically active additives based on water-soluble proteins contained in salmon fishes liver. The method involves initial raw material selection, extraction, solid fraction separation, target product decontamination and drying. The initial raw material is represented by salmon fishes liver (fresh, frozen or dried). Extraction is performed with distilled water, the raw material to extractive agent ratio being 1:5 -1:30 which is followed by the suspension alkalisation till pH is 8-9 and infusion at room temperature during 2-4 h accompanied by stirring. Then one proceeds with the target product decontamination by way of the solid fraction treatment with a 0.3% solution of chitosan in a 3% solution of an organic food acid, pH being 2.5-3.0 in a 1:20 ratio during 1 h accompanied by stirring with subsequent incubation of the mixture during 2-3 h. One performs double separation into the solid and the liquid fractions with subsequent depletion of the liquid fractions.

EFFECT: invention allows to produce a water-soluble polypeptide complex of salmon fishes liver which is characterised by a balanced amino acid composition, an enhanced taurine content and a high antioxidant activity.

2 cl, 3 dwg, 1 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to cardiology and angiology, and deals with correction of functions of vascular walls in patients with arterial hypertension of I-II degree with metabolic syndrome, after thrombosis of eye vessels. For this purpose indices of anti-aggregate, anti-coagulant and fibrinolytic activity of vascular wall are determined. On the basis of said indices calculated is total anti-thrombotic potential of vessels and if its value is 0.069 and lower, complex treatment, including application of individually selected hypocaloric diet, dosed physical load, pioglitazone 30 mg 1 time per day and valsartan 160 mg 1 time per day in the morning during 4 months, is administered.

EFFECT: complex of drug and non-drug therapy in combination with empirically selected duration of treatment ensures correction of functions of vascular wall and, thus, reduction, of risk of thrombotic complications in said group of patients due to potentiation of therapeutic effect of separate components of therapeutic complex.

1 ex, 1 dwg

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to cardiology and angiology, and deals with correction of functions of vascular walls in patients with arterial hypertension of III degree with metabolic syndrome, after thrombosis of eye vessels. For this purpose indices of anti-aggregate, anti-coagulant and fibrinolytic activity of vascular wall are determined. On the basis of said indices calculated is total anti-thrombotic potential of vessels and if its value is 0.069 and lower, complex treatment, including application of individually selected hypocaloric diet, dosed physical load, pioglitazone 30 mg 1 time per day and valsartan 80 mg 1 time per day in the morning and amlodipine 10 mg 1 time per day during 4 months, is administered.

EFFECT: complex of drug and non-drug therapy in combination with empirically selected duration of treatment ensures correction of functions of vascular wall and, thus, reduction, of risk of thrombotic complications in said group of patients due to potentiation of therapeutic effect of separate components of therapeutic complex.

1 ex, 1 dwg

FIELD: medicine.

SUBSTANCE: in adolescent female patients with overweight suffering menstrual disorders of oligomenorrhea or amenorrhea type are examined for a body weight index (BWI) and blood serum leptin level measured by enzyme immunoassay. And if the BWI of the patient exceeds 25.0 kg/m2, and the leptin level is less than 32.52 ng/ml, diet therapy and graduated physical activity are prescribed. The leptin level 32.52 ng/ml and higher in the patient requires additional glucose tolerance test to a common technique to detect insulin resistance. If observing insulin resistance, the complex treatment includes the preparations to provide higher peripheral tissue sensitivity (sensitisers) to insulin. The absence of insulin resistance enables to prescribe the therapy of combined oral contraceptives with drospirenone.

EFFECT: method allows prescribing well-timed adequate therapy for treating said disease and evaluating the efficacy of the performed therapy.

3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely - to reflexotherapy, psychiatry, addictology. At the withdrawal syndome peak, a complex treatment involves millimeter wave therapy (MWT) of biologically active points (BAP) and nutrition. The MWT exposure is conducted in a pseudonoise radiation mode, frequency range 54 - 70 GHz, output power up to 0.3 mWt, procedure duration 30 minutes. The main MWT procedures are performed on 1st-5th and 8th-9th therapeutic days. In 1 and 6 months, supportive therapeutic courses including 1-3 MWT sessions are carried out. In the patients with a body weight index (BWI) not exceeding 25 units, nutrition does not require caloric value limitation. In the patients with the BWI exceeding 25 units, nutrition requires caloric value limitation. That is ensured by limited consumption of simple carbohydrates and animal fats up to 10 % each from the caloric value, and by enrichment with protein up to 25 % from the caloric value, with vegetable fats - up to 20 % from the caloric value, with cellulose - up to 30 g.

EFFECT: method provides the prevention of body weight gain and other withdrawal syndrome manifestations during smoking cessation without additional use of a drug-induced therapy.

2 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to cardiology and angiology, and deals with normalisation of functional activity of vessel wall in patients with arterial hypertension of I-II degree with metabolic syndrome, after thrombosis of eye vessels. For this purpose, indices of anti-aggregation, anti-coagulation and fibrinolytic activity of vascular wall are determined. On the basis of said indices general anti-thrombotic potential of vessels is calculated and if its value is 0.069 and lower, administered is complex treatment, including application of individually selected hupocaloric diet, dosed physical load, introduction of pioglitazone in dose 30 mg 1 time per day and lisinopril in dose 20 mg 1 time per day for 4 months.

EFFECT: complex of drug and non-drug therapy in combination with empirically selected treatment duration ensures complete normalisation of functional activity of vascular wall and, thus, reduction of risk of thrombotic complications in said group of patients due to potentiation of therapeutic effect of separate components of medicinal complex.

2 ex, 1 dwg

FIELD: food industry.

SUBSTANCE: probiotic composition for infant food includes Bifidobacterium breve, undigestible saccharide A and undigestible saccharide B with a degree of polymerisation between 2 and 200, additionally contains Lactobacillus paracasei. The composition has a viscosity 1-6 MPa·s, a caloric content 10 and 250 kcal per 100 ml. The said composition is applied for food composition production for usage in a method for provision of infant food, for production of a composition for prophylactic and/or treatment of gastrointestinal diseases, immune diseases and/or endocrinopathy, for prophylactic and/or treatment of allergy, atopic dermatitis, eczema and/or infection.

EFFECT: invention ensures possibility to imitate infant indestinal flora at breastfeeding, optimal composition caloric content promotes to reduce diarrhea, immune diseases, endocrinopathy and allergy.

17 cl, 1 dwg, 4 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention is related to a food product for AIDS patients. Proposed is a food composition containing one or more acidic oligosaccharide(s) and one or more neutral oligosaccharide(s) and cysteine and/or a cysteine source. The acidic oligosaccharides are produced from pectin, pectate, alginate, chondroitin, hyaluronic acids, heparin, heparan, sialoglycanes, fucoidan, fucooligosaccharides or carageenan. The neutral oligosaccharides are selected from a group consisting of galactooligosaccharide, fructooligosaccharide, transgalactooligosaccharide, xylooligosaccharide, lactosucrose and arabinooligosaccharide where the said cysteine source is represented by N-acetylcysteine and/or diacetylcysteine, whey, beestings, egg whites or combination thereof.

EFFECT: invention enables preclusion and prevention of AIDS-related disfunctions.

12 cl, 1 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: invention is related to alimentation, in particular - to a method and composition for improvement of glucose and insulin balance. Proposed is a compound that includes: a protein source, a fat source and a carbohydrate source, the protein source to the fat source ratio being approximately 1:1:1, each source accounting for 15% - 45% of the total calorie content of the compound. The fat source accounts for approximately over 2% of the total calorie content of the composition in the form of linoleic acid (18:2). According to an alternative version, the food compound for normalisation of insulin and glucose in the organism contains a protein source, a fat source and a carbohydrate source at a ratio of 1:1:1, each of these components accounting for approximately a third of the total calorie content of the compound. Additionally proposed are a diet for enhancement of sensitivity to insulin, a method to reduce resistivity to insulin, a method to reduce insulin levels in the plasma during after dinner time, a method to delay occurrence of insulin in one's blood and a method to increase fat clearance during after dinner time envisaging usage of the above food compound.

EFFECT: invention allows to improve glucose regulation and insulin effect.

68 cl, 34 dwg, 38 tbl

FIELD: food industry.

SUBSTANCE: invention relates to a nutritive supplement, to a method of its production and application. The nutritive supplement, according to the invention, contains a protein source including milk protein isolate and/or canola protein, a fat source, a carbohydrate source and water and has calorific value 2.25 - 3.25 cal/ml and viscosity lower than 120 centiPoise. The method for production of the supplement envisages a mixture preparation of water and the protein source, the fat source, the carbohydrate source, the mixture treatment with direct injection of vapour, the mixture homogenisation. The nutritive supplement, according to the invention, is applied in combination with one or more medicaments during therapy of nutritional deficiency. The nutritive supplement has high calorific value and will be useful for persons suffering from body weight loss.

EFFECT: milk protein isolate treatment with application of direct injection of vapour allows to reduce viscosity of the nutritive supplement.

20 cl, 4 tbl, 12 ex

FIELD: food industry.

SUBSTANCE: invention is related to alimentary therapy. Proposed is a method providing for a cancer patient long-term alimentation and envisaging long-term administration of a nutritional product to the patient through a probe, the product containing a protein source providing for 14-25% of the product energy value and composed of whey (50% of energy value), glutamine (0.5% - 10% of energy value), leucine (0.8% - 3.5% of energy value), a carbohydrate source (20-55% of the product energy value) and a lipid source ( 25-40% of the product energy value). Optionally, the method envisages first administration of the above composition to a tumour cancer patient (through a probe) and then, upon normal metabolic status recovery - administration of a second composition for long-term alimentation that differs from the first composition in terms of formulation. Optionally, the method providing for a cancer patient long-term alimentation envisages administration of glutamine together with the above nutritional composition at least a week prior to commencement of the cancer therapy course.

EFFECT: invention enables to ensure well-balanced and efficient long-term through-probe alimentation of a cancer patient.

36 cl, 4 ex

FIELD: food industry.

SUBSTANCE: invention relates to a nutritional composition for babies. The composition includes a lipidic component and a digestible carbohydrate component. The lipidic component includes linolic acid (LA) and alpha-linolic acid (ALA), the LA/ALA weight ratio being from 2 to 7, the amount of LA being less than 14.5 wt %. of the total weight of fatty acids, the amount of ALA being from 1 wt % to 10 wt % of the total weight of fatty acids. The composition additionally includes at least one component chosen from the group consisting of: from 0.5 to 20 wt % of phospholipids of the total fat weight; from 0.035 to 1 wt % of choline of the total weight of the dry composition and from 0.001 to 0.1 wt % of uridine in the form of nucleotide, nucleoside and/or base of the total weight of the dry composition.

EFFECT: invention allows to prevent adiposity occurrence at an age of over 36 months by way of feeding the said nutritional composition to the baby at an age of under 36 months.

16 cl, 5 tbl, 4 ex

Up!